English
Español
Pусский
Français
Deutsch
简体中文
COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit is an In Vitro Diagnostic (IVD) reagent replying on fluorescent PCR technology and aiming at qualitatively detection and differentiation of human RNA from SARS-CoV-2 from upper and lower respiratory tract samples. Primer and probe are selected fromOpen Reading Framegene region (ORF1a/b),envelope protein (E)andnucleocapsid region (N)for SARS-CoV-2. The kit is a multiplex assay, run in a single well/vessel, designed for detection and differenti
In October 2020, SARS-CoV-2 lineage B.1.617 emerged in India, causing an exponential increase in COVID-19 cases across the country. The lineage is further divided into three subgroups: B.1.617.1, B.1.617.2, and B.1.617.3, of which the B.1.617.2 variant (also known as Delta variant) has been designated as Variant of Concern (VOC) by WHO because of significantly increased infectivity. The mutations L452R and E484Q, along with P681R in the furin cleavage site are reported to lead to increased ACE
SARS-CoV-2 Lambda (C.37) variant was first detected in Peru in December 2020 and has been designated as a VOI by the WHO in June 2021, due to a heightened presence of this variant in Peru, Chile, United States of America, Argentina, etc.The spike protein of the Lambda variant is more infectious, which is attributed to the T76I and L452Q mutations. Another mutation F490S has already been associated with reduced susceptibility to antibodies generated in patients who had recovered from COVID. Thi
On Nov. 24, 2021, the variant B.1.1.529 was first identified in South Africa, and only two days later, WHO announced that B.1.1.529 constitutes a variant of concern, named Omicron. There are more than 30 mutation sites on the S gene of variant B.1.1.529. Omicron has a greater binding affinity than the original SARS-CoV-2 virus, with levels more comparable to what we see with the Delta variant. Some of the mutations have been detected in previous variants, such as Alpha and Delta, and have been
The Bioperfectus Technologies Novel Corona Virus(SARS-CoV-2)Ag Rapid Test Kit including Prepacked Extraction Tube is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swabs from individuals who are suspected of COVID-19 within the first seven days of the onset of symptoms. Fast: results within 15 minutesEasy to use: prepacked design makes testing more convenientHumanized: all necessary components providedFlexible: different
The Novel Corona Virus(SARS-CoV-2)IgM/IgG Rapid Test Kit from Bioperfectus is an in vitro diagnostic test used for the detection of novel coronavirus (SARS-CoV-2) IgM and IgG antibodies. This product is based on immunochromatographic technology. The detection area of the strip has an IgM test line (T2 line), an IgG test line (T1 line) and a control line (C line). Fast results within 10-15 minutesEasy to use: 3 steps to finish the testQuality control: ensure the result is reliableMultiple
I am interested in learning more about the BioPerfectus product
Fieids marked with an asterisk(*) are required